120 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. Written … litigation under federal and state statutes, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially
6-K
EX-99.1
OBSVF
ObsEva SA
19 Dec 22
ObsEva Announces Dismissal of Moratorium Proceedings
8:30am
that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act
6-K
EX-99.1
OBSVF
ObsEva SA
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect
6-K
EX-99.1
OBSVF
ObsEva SA
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS INDENTURE.
Section 13.06 Treatment
6-K
EX-99.3
dzk2rc oxmua0quv
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
eeqbr10f9dzmq58wl
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
ettxhxc
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
ggd33bug8
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
bcgpvu8g6x7dowvsu
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
xpghkt32fapmrpo
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
7dr 05w6y
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
EX-99.1
yyd0k118 4qibkz
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K
EX-99.1
9xo77w1qxjg1x zpc
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
k2lp0dsv
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
8qz 4ruif6qz
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
zya 4qemihkz
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
EX-99.1
alu ns4ee
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
EX-99.1
gb56 nr8846
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.2
969ycv4d 7ajb7jjr
27 Jul 22
ObsEva Announces Corporate Updates
7:03am